Trial · NCT06868745
Effects of Melatonin Supplementation on Sleep Quality in Patients With Advanced Glaucoma
NCT06868745, Not applicable, Completed, University of Sao Paulo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Melatonin Supplementation on Sleep Quality in Patients With Advanced Glaucoma. Trials, record NCT06868745. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06868745
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Melatonin Supplementation on Sleep Quality in Patients With Advanced Glaucoma
- NCT number
- NCT06868745
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 64 participants, actual
- Lead sponsor
- University of Sao Paulo
- Conditions
- Glaucoma, Sleep Disturbance, Circadian Rhythm, Melatonin, Actigraphy
- Interventions
- Experimental: melatonin treatment group, Placebo comparator: placebo treatment group
- First posted
- 2025-03-11
- Last updated
- 2025-03-11
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effects of Melatonin Replacement on Sleep Quality of Patients with Advanced Glaucoma | From enrollment to the end of treatment in 2 months | To compare the quality of sleep in patients with advanced glaucoma after 30 days of melatonin 5 mg and 30 days of placebo. The comparison of efficacy between groups will be assessed based on the improvement in sleep quality between medications. |
| Secondary | Effects of Melatonin Replacement on Sleep Quality of Patients with Advanced Glaucoma | From registration to the end of treatment in 2 months | To compare the effects on sleep quality after using melatonin 5 mg and placebo. The effects on sleep quality will be measured by the following assessments: questionnaire (Pittsburgh Sleep Quality Index). Sleep quality is measured on a 7-level scale, with the last level being the worst rating; |
| Secondary | Effects of Melatonin Replacement on Sleep Quality of Patients with Advanced Glaucoma | From registration to the end of treatment in 2 months | To compare the quality of sleep in patients with advanced glaucoma after 30 days of melatonin 5 mg and 30 days of placebo. The comparison of efficacy between groups will be assessed based on the improvement in sleep quality between medications, using the actigraph, which will analyze the total sleep time through minutes slept, between the groups, the longer the time slept, the better quality of sleep, and also analyzes the number of awakenings, how many times during sleep the patient wakes up, the greater the number of awakenings, the worse the quality of sleep. |
| Secondary | Effects of Melatonin Replacement on Sleep Quality of Patients with Advanced Glaucoma | From registration to the end of treatment in 2 months | To compare the effects on sleep quality after using melatonin 5 mg and placebo. The effects on sleep quality will be measured by the following assessments: questionnaire, Epworth Sleepiness Scale, level of excessive sleepiness is measured on 8 levels, with the last level being the worst rating; |
| Secondary | Effects of Melatonin Replacement on Sleep Quality of Patients with Advanced Glaucoma | From registration to the end of treatment in 2 months | To compare the effects on sleep quality after using melatonin 5 mg and placebo. The effects on sleep quality will be measured by the following assessments: questionnaire, 25-Item National Eye Institute Visual Function Questionnaire, quality of life is measured on 25 levels, with the last level being the best rating. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06868745
GET https://conductscience.org/api/trials/v1/NCT06868745/registered